TNX-103 is named as a drug or biological intervention in 3 clinical trials in our USA and UK trial registers, 1 of which is recruiting. The lead sponsor is Tenax Therapeutics, Inc.. Registered phase: Phase 3. Conditions studied include Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07288398 | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (ClinicalTrials.gov ↗) Pulmonary Hypertension Associated With HFpEF |
Phase 3 | Recruiting |
| NCT07436689 | Long-Term Open-Label Extension Study of Oral Levosimendan Pulmonary Hypertension Associated With HFpEF |
Phase 3 | By invitation |
| NCT05983250 | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF Pulmonary Hypertension |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Pulmonary Hypertension Associated With HFpEF | 2 |
| Pulmonary Hypertension | 1 |
| Lead sponsor | Trials |
|---|---|
| Tenax Therapeutics, Inc. | 3 |
| Register | TNX-103 trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TNX-103 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TNX-103 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.